MA33003B1 - Solutions pediatriques comprenant un betabloquant - Google Patents

Solutions pediatriques comprenant un betabloquant

Info

Publication number
MA33003B1
MA33003B1 MA34064A MA34064A MA33003B1 MA 33003 B1 MA33003 B1 MA 33003B1 MA 34064 A MA34064 A MA 34064A MA 34064 A MA34064 A MA 34064A MA 33003 B1 MA33003 B1 MA 33003B1
Authority
MA
Morocco
Prior art keywords
blockers
treatment
solution
containing beta
children containing
Prior art date
Application number
MA34064A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Christine Chaumont
Jean-François Cordoliani
Elie Leverd
Valérie Muguet
Original Assignee
Fabre Pierre Dermo Cosmetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40940328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33003(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fabre Pierre Dermo Cosmetique filed Critical Fabre Pierre Dermo Cosmetique
Publication of MA33003B1 publication Critical patent/MA33003B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA34064A 2009-04-21 2010-04-12 Solutions pediatriques comprenant un betabloquant MA33003B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290298A EP2246044A1 (de) 2009-04-21 2009-04-21 Kinderärztliche Lösungen für Betablocker
PCT/IB2010/051573 WO2010122442A1 (en) 2009-04-21 2010-04-12 Paediatric solutions comprising a beta-blocker

Publications (1)

Publication Number Publication Date
MA33003B1 true MA33003B1 (fr) 2012-01-02

Family

ID=40940328

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34064A MA33003B1 (fr) 2009-04-21 2010-04-12 Solutions pediatriques comprenant un betabloquant

Country Status (32)

Country Link
US (2) US20120035270A1 (de)
EP (4) EP2246044A1 (de)
JP (1) JP5695029B2 (de)
KR (1) KR101713866B1 (de)
CN (1) CN102405041A (de)
AR (2) AR076338A1 (de)
AU (1) AU2010240551B2 (de)
BR (1) BRPI1015447B1 (de)
CA (1) CA2755175C (de)
CL (1) CL2011002634A1 (de)
CO (1) CO6410278A2 (de)
CY (2) CY1119390T1 (de)
DK (2) DK2421504T4 (de)
ES (2) ES2623936T5 (de)
GE (1) GEP20146087B (de)
HR (2) HRP20170610T4 (de)
HU (2) HUE034581T2 (de)
IL (1) IL214674A (de)
LT (2) LT2421504T (de)
MA (1) MA33003B1 (de)
MX (1) MX337463B (de)
NZ (1) NZ594592A (de)
PL (2) PL2421504T5 (de)
PT (2) PT2421504T (de)
RS (2) RS57668B2 (de)
RU (1) RU2011139233A (de)
SG (1) SG172960A1 (de)
SI (2) SI2497461T2 (de)
TN (1) TN2011000350A1 (de)
TW (1) TWI429459B (de)
UA (1) UA107570C2 (de)
WO (1) WO2010122442A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246044A1 (de) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Kinderärztliche Lösungen für Betablocker
CN107088226A (zh) * 2011-03-04 2017-08-25 格吕伦塔尔有限公司 他喷他多的胃肠外给药
EP2680832B1 (de) 2011-03-04 2019-09-04 Grünenthal GmbH Wässrige pharmazeutische formulierung von tapentadol zur oralen verabreichung
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
US9724297B2 (en) 2014-04-01 2017-08-08 Arbor Pharmaceuticals, Inc. Sotalol compositions and uses of the same
MX2017012312A (es) 2015-03-27 2018-01-18 Gruenenthal Gmbh Formulacion estable para administracion parenteral de tapentadol.
KR20190057349A (ko) 2016-09-23 2019-05-28 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여용 안정한 제제
CN108261411B (zh) * 2016-12-30 2021-04-30 武汉科福新药有限责任公司 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法
CN107320467A (zh) * 2017-07-21 2017-11-07 江苏云阳集团药业有限公司 一种盐酸普萘洛尔药用组合物及其制备方法
CN108299279B (zh) * 2018-02-09 2021-03-23 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
US11547123B2 (en) * 2019-08-16 2023-01-10 The Folger Coffee Company Methods for reducing negative flavor attributes in coffee and compositions therefrom
EP4223283A1 (de) 2020-09-30 2023-08-09 Nissan Chemical Corporation Wasserlöslicher komplex mit betablocker und lecithin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600708A (en) 1985-07-19 1986-07-15 American Home Products Corporation Propranolol hydrochloride liquid formulations
HU209251B (en) 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
DE69613164T2 (de) 1995-03-15 2001-09-27 Kao Corp Verwendung eines Zusatzstoffes zur Verminderung von Bittergeschmack
JPH1025253A (ja) * 1996-07-12 1998-01-27 Kao Corp 苦味低減化剤及び苦味低減化法
JPH11349492A (ja) * 1998-06-03 1999-12-21 Yamanouchi Pharmaceut Co Ltd 苦味を低減した経口用医薬組成物および苦味低減化方法
JP2001342151A (ja) * 2000-03-31 2001-12-11 Eisai Co Ltd 甘味を有する薬剤組成物
ATE334656T1 (de) * 2001-05-25 2006-08-15 Warner Lambert Co Flüssige pharmazeutische zusammensetzung
EP1543831A1 (de) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Zusammensetzung enthaltend Pregabalin
CA2597155A1 (en) * 2005-02-25 2006-09-08 Biomarin Pharmaceutical Inc. Room temperature stable aqueous liquid pharmaceutical composition
RU2007148444A (ru) * 2005-05-25 2009-06-27 Янссен Фармацевтика Н.В. (Be) Педиатрическая композиция топирамата
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
EP2050441A1 (de) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Verwendung von Beta-Blockern für die Herstellung eines Medikaments zur Behandlung von Hämangiomen
DK2268282T3 (en) * 2008-04-25 2014-11-24 Apotex Technologies Inc Liquid formulation of deferiprone with pleasant taste
EP2246044A1 (de) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Kinderärztliche Lösungen für Betablocker

Also Published As

Publication number Publication date
PL2421504T5 (pl) 2023-01-02
HRP20170610T4 (hr) 2022-12-09
RS57668B1 (sr) 2018-11-30
PT2497461T (pt) 2018-10-23
HRP20181408T1 (hr) 2018-11-02
AU2010240551B2 (en) 2015-07-16
CA2755175A1 (en) 2010-10-28
EP2421504B1 (de) 2017-03-08
CY1119390T1 (el) 2018-02-14
US20150087719A1 (en) 2015-03-26
DK2421504T4 (da) 2022-11-14
TWI429459B (zh) 2014-03-11
BRPI1015447A2 (pt) 2016-04-19
AR076338A1 (es) 2011-06-01
HUE039937T2 (hu) 2019-02-28
RS57668B2 (sr) 2022-03-31
KR20120015305A (ko) 2012-02-21
HUE034581T2 (en) 2018-02-28
BRPI1015447B1 (pt) 2020-01-28
PL2497461T3 (pl) 2018-12-31
IL214674A (en) 2017-01-31
SG172960A1 (en) 2011-08-29
EP2246044A1 (de) 2010-11-03
ES2623936T5 (es) 2022-11-28
ES2685178T5 (es) 2022-04-13
HRP20170610T1 (hr) 2017-07-28
CY1120667T1 (el) 2019-12-11
TW201039862A (en) 2010-11-16
CO6410278A2 (es) 2012-03-30
EP2497461A3 (de) 2014-01-01
JP5695029B2 (ja) 2015-04-01
RS55862B2 (sr) 2022-12-30
TN2011000350A1 (en) 2013-03-27
SI2497461T1 (sl) 2018-10-30
LT2421504T (lt) 2017-06-12
ES2623936T3 (es) 2017-07-12
KR101713866B1 (ko) 2017-03-09
PL2497461T5 (pl) 2022-06-27
LT2497461T (lt) 2018-10-10
HRP20181408T4 (hr) 2022-03-04
EP2497461A2 (de) 2012-09-12
SI2421504T1 (sl) 2017-06-30
EP2497461B2 (de) 2021-12-15
NZ594592A (en) 2013-11-29
JP2012524773A (ja) 2012-10-18
MX2011010766A (es) 2011-10-21
AR117621A2 (es) 2021-08-18
BRPI1015447A8 (pt) 2017-10-03
RS55862B1 (sr) 2017-08-31
IL214674A0 (en) 2011-09-27
CL2011002634A1 (es) 2012-06-08
CN102405041A (zh) 2012-04-04
EP2421504A1 (de) 2012-02-29
EP2497461B1 (de) 2018-06-20
PL2421504T3 (pl) 2017-08-31
MX337463B (es) 2016-03-07
EP2421504B2 (de) 2022-08-10
ES2685178T3 (es) 2018-10-05
US20120035270A1 (en) 2012-02-09
WO2010122442A1 (en) 2010-10-28
DK2421504T3 (en) 2017-05-01
CA2755175C (en) 2018-01-02
SI2497461T2 (sl) 2022-04-29
RU2011139233A (ru) 2013-05-27
DK2497461T3 (en) 2018-09-03
EP3384899A1 (de) 2018-10-10
UA107570C2 (xx) 2015-01-26
GEP20146087B (en) 2014-05-13
AU2010240551A1 (en) 2011-08-04
DK2497461T4 (da) 2022-02-14
PT2421504T (pt) 2017-06-16

Similar Documents

Publication Publication Date Title
MA33003B1 (fr) Solutions pediatriques comprenant un betabloquant
HK1112843A1 (en) Oral, quickly disintegrating film, which cannot be spit out, containing olanzapin
WO2008137785A3 (en) Water treatment system and downstream cleaning methods
MA35273B1 (fr) Composition nettoyante
WO2007096885A3 (en) Formulations containing a non-oxidative biocide and a source of active halogen and use thereof in water treatment
UA91867C2 (ru) Применение жидкой композиции на основе гуанидинуксусной кислоты и готовый питьевой продукт, содержащий ее
WO2009007411A3 (fr) Inhibition de la formation des ages
EA200870057A1 (ru) Минеральная вода на основе молока, способы ее получения и напитки, содержащие минеральную воду на основе молока
WO2007124476A3 (en) Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
BRPI0811881A8 (pt) Condimento, alimento ou bebida, composição, e método para melhorar o sabor de um sal de potássio
FR2904756B1 (fr) Dispositif de maintien des seins pour application medicale.
WO2007019276A3 (en) Quantitative detection of lead in water
FR2928838B1 (fr) Dispositif de raccordement/protection de capteur, en particulier pour des lignes biomedicales d'hemodialyse
BR112013030904A2 (pt) Composição de peptídeos, composição de aroma, e, alimento ou bebida
WO2009083520A3 (fr) Compositions orales liquides de florfenicol diluables dans l'eau de boisson
FR2915209B1 (fr) Dispositif pour l'entretien des canalisations notamment le detartrage et la desoxydation.
WO2009080349A3 (en) Bottling and brewing cleaning-in-process water management
WO2007017259A3 (de) Verwendung von spezifischen trifluormethylketonen zur vorbeugung und behandlung einer pankreatitis
Schoenstein Determination of Bromate by different IC and IC/MS methods
张晨 Concentration Hampers Simple Tasks
EA201390882A1 (ru) Напитки на основе чая
RU2007130033A (ru) Безалкогольный напиток "жидкий лед"
Rivière et al. Approche de la sous-déclaration des troubles musculo-squelettiques dans 10 régions françaises en 2009
Sutcliffe Women's literacy in Old Russia: hypotheses and facts
UA29354U (en) "karpatska osoblyva" special vodka